Targeting both EGFR and VEGF-A via a bispecific antibody binding potentially enhances anti-tumor activity not only by inhibiting EGFR signaling in OC, but also by blocking angiogenic activity in endothelial cells that support tumor growth and progression. Here, VEGFA is linked to neoplasm.